Dr. Raffit Hassan
University of Kashmir, Hazratbal, India - 1988
Sisters of Charity Hospital, Buffalo, NY
National Cancer Institute, Bethesda, MD
Dr. Raffit Hassan is a medical oncologist who currently serves as co-chief of the Thoracic and Gastrointestinal Oncology Branch and senior investigator of the Head, Thoracic and Solid Tumor Immunotherapy Section at the Center for Cancer Research, National Cancer Institute (NCI) located in Bethesda, Maryland. Prior to his employment at the NCI where he received tenure in 2008, Dr. Hassan was a member of the medical faculty at the University of Oklahoma.
Dr. Raffit Hassan earned his medical degree from the University of Kashmir in India in 1988. He then went on to complete his internship and residency in internal medicine at the Sisters of Charity Hospital in Buffalo, New York. A medical oncology fellowship ensued at the NCI in Bethesda, Maryland. In 2002, four years after completing his fellowship, Dr. Hassan returned to the NCI as a tenure track investigator.
Clinical and Laboratory Research
Dr. Hassan’s research focus is on the development of targeted immunotherapy, in particular immunotoxins, for patients diagnosed with malignant mesothelioma and other tumors. His laboratory is currently exploring mesothelin-targeted agents for cancer treatment, among them an anti-mesothelin immunotoxin, SS1P, which has been validated in both preclinical studies and early phase clinical trials as a therapeutic target for cancer therapy. Dr. Hassan and his team of researchers are now investigating means by which to increase the efficacy of SS1P in patients, as well as how to develop less immunogenic immunotoxins as viable options for cancer treatment. At the present time, Dr. Hassan is the lead investigator on five clinical trials recruiting mesothelioma patients.
A noted researcher and published author, Dr. Hassan’s work has been featured in prominent, scientific, peer-reviewed journals such as Clinical Cancer Research, Journal of Thoracic Oncology, Cancer Research, and Science Translational Medicine, among others. He is the recipient of several awards, including the NIH Patient Oriented Research Career Development Award, the Pioneer Award from the Mesothelioma Foundation, and the American Society of Clinical Oncology (ASCO) Career Development Award. Through his work, Dr. Hassan offers the potential for new therapeutic treatment options to mesothelioma patients worldwide.
Dr. Hassan’s published articles relative to mesothelioma research and treatment:
National Center for Biotechnology Information, U.S. National Library of Medicine—PubMed
The National Institutes of Health
Center for Cancer Research/National Cancer Institute